Sangamo Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Advanced BLA submission for Fabry gene therapy with FDA reaffirming no need for a second confirmatory study. Progressed neurology pipeline, transitioned to OTCQB after Nasdaq delisting, and actively pursuing capital and strategic partnerships.
Fiscal Year 2025
-
Positive clinical results in Fabry disease and neurology programs drove pipeline progress, with a rolling BLA submission for ST-920 underway and Fast Track designation for ST-503. Over $130 million was raised, but continued operations depend on securing additional funding and a Fabry commercialization partner.
-
Advanced clinical programs in Fabry disease and neurology, with positive ST-920 data and FDA support for accelerated approval. Cash runway extends into Q1 2026, with ongoing business development and partnership efforts to secure long-term funding.
-
Positive top-line results in Fabry disease support accelerated approval, with strong patient and physician enthusiasm. Cash runway extends into Q4 2025, and key neurology and prion programs advanced, while business development for commercialization partnerships remains a top priority.
-
Signed a major licensing deal with Lilly, advanced neurology and Fabry programs, and reduced operating expenses by 50% year-over-year. Cash runway now extends to late Q3 2025, with pivotal Fabry data and a BLA submission expected in the coming quarters.
-
Key programs are advancing, with Fabry disease filing and partnership expected in 2024, and a first-in-class Nav1.7 gene therapy entering the clinic for neuropathic pain. Financial runway is supported by ongoing capsid deals, and Hemophilia A data transfer from Pfizer is progressing.
Fiscal Year 2024
-
Advanced neurology and Fabry programs, with pivotal Fabry data expected mid-2025 and strong financial discipline shown. Over $100M raised in 2024, with key partnerships and regulatory milestones driving future growth.
-
Major regulatory advances enable accelerated approval for Fabry disease, with BLA submission expected in 2025. $50M from Genentech and up to $220M in Pfizer milestones strengthen financial outlook, while neurology and prion programs progress toward clinical trials.
-
Major Genentech partnership and positive Phase 3 Hemophilia A results validate the scientific platform and provide significant near-term funding. Fabry program shows durable clinical benefit and ongoing partnership interest, with additional deals expected in 2024.